Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors - Wikidata - wikimedia - TriplyDB

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

http://www.wikidata.org/entity/Q35116206

about

Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data.Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975].Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.Erlotinib resistance in lung cancer: current progress and future perspectives.EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation.Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.Excessive Reversal of Epidermal Growth Factor Receptor and Ephrin Signaling Following Tracheal Occlusion in Rabbit Model of Congenital Diaphragmatic Hernia.Afatinib treatment in advanced non-small cell lung cancer.New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer.The study of homology between tumor progression genes and members of retroviridae as a tool to predict target-directed therapy failure.[EGFR-dependent impact of indol-3-carbinol on radiosensitivity of lung cancer cells].

P2860

Q26739777-C227F86C-D9DA-46C4-9657-D2B29EF1DCB2 Q28115136-93B4050C-5B13-4639-A54E-E7FE98564551 Q30701832-4CF3331A-3198-4769-8A4A-7615544B932D Q33812445-E28C10B5-2199-4ECC-BE04-FDFBC72E23DC Q34201724-228427D6-DE69-4981-9FDE-51A248B632C7 Q34205052-D7DB78C1-D422-446E-A970-EC44EDF9C6EA Q35876204-EA1F799C-A074-4664-B09D-AAE96CA77C12 Q36605522-F16E71F2-62AA-4428-99BB-81C759AEA5FF Q36619212-23B1F5F8-3ADB-410A-A138-D23C7DCBABB4 Q36942619-655B88DC-BF57-478D-BECF-94501301470F Q37353953-FFE441C8-0A41-4A3C-9294-CC0235C9EAF0 Q37645209-88775E68-80E0-4079-832D-6CC162BCD3D3 Q39139889-402E9084-D47A-4DD5-8E24-6D57F2FAC4E8 Q40151542-635812C3-7ADC-4E6F-BCB1-E7304961D8FE Q54496147-192C900B-8BAF-43FE-AB4E-74277B87B35B

P2860

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

http://www.wikidata.org/entity/Q35116206

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

@ast

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

@en

type

label

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

@ast

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

@en

prefLabel

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

@ast

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

@en

P1433

Q35116206-2B51BC34-E540-4008-BC35-A075FE964692

P1476

Q35116206-2B27AA0A-434B-4752-A34C-2B0714055541

P2093

Q35116206-1067E9C3-7A46-4FBB-90B3-F882947E3292

P2860

Q35116206-002D5606-760E-453E-850F-9DB56F4C5AB1

Q35116206-0A73DA2B-52FD-4D67-97F7-DAB0AD581115

Q35116206-0D4B383D-F089-4B5C-8C88-B3EE49F487D8

Q35116206-125290CA-F2F6-4B55-92CB-248F7BCABCB3

Q35116206-19CC8F90-4BFC-4FC0-878F-353363B9565A

Q35116206-1AD19C7D-5F86-4AD4-9B3A-A30B0DA0BAF9

Q35116206-1AE46018-374A-4081-930E-DA215D900BC5

Q35116206-1FB8ABC1-ED7F-489D-A08A-0AE0972C3C5D

Q35116206-24B4B782-3329-4828-A721-B82BAA70D13B

Q35116206-2A93C046-FB14-41F8-9F0D-E7A7BA38527E

P304

Q35116206-05C20966-A83A-433F-A420-AA5D1E87F807

P31

Q35116206-28660BC7-5BB3-4E13-85D6-5FF2E2A540BD

P356

Q35116206-E53109CE-F6EA-44C8-97B9-497B19DB201A

P433

Q35116206-5468DD5E-E912-4A2E-AC74-7B2FD36BDD7E

P478

Q35116206-E07CE084-87ED-407C-870A-F58EE2843DA2

P50

Q35116206-39B34D09-528C-452E-8CBF-A93416B396DD

P577

Q35116206-C9B1574B-21D5-4A7E-AFDC-C267A20EF2EF

P5875

Q35116206-9966FF69-1B9B-447C-9E9E-633C03B8654B

P698

Q35116206-61A6E5E6-4C76-4BBE-8718-4D5B3759A944

P932

Q35116206-00F01450-1957-4F79-AF75-6B6B65CB01CA

P356

J.CTRV.2011.01.003

P1433

Cancer Treatment Reviews

P1476

Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors

@en

P2093

Yisong Wang

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

P304

456-464

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CTRV.2011.01.003

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Giaccone

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50266538

http://www.w3.org/2001/XMLSchema#string

P698

21367530

http://www.w3.org/2001/XMLSchema#string

P932

3139833

http://www.w3.org/2001/XMLSchema#string